The Cell and Gene Therapy CRO Service Market refers to companies that provide outsourced research services to support the development and commercialization of cell and gene therapies. This is a fast-growing segment of the broader CRO market valued at over $5 billion in 2022.

Cell and gene therapies involve introducing new cells or modifying existing cells in the body to treat disease. As these therapies have become more advanced in recent years, biotech and pharmaceutical companies developing them require specialized expertise and infrastructure to run clinical trials and navigate regulatory approvals. Since most lack these capabilities in-house, they partner with cell and gene therapy CROs.

Major services offered by cell and gene therapy CROs include cell processing/manufacturing, clinical trial management, regulatory/quality oversight, lab testing, data management, logistics, and consulting. Key end-user markets are companies developing CAR-T cancer immunotherapies, stem cell therapies, gene therapies, and regenerative medicines. Drivers of the growth in this CRO market include increased RD investment in cell/gene therapy and faster adoption of personalized medicines.

The high capital requirements and expertise needed for this specialized CRO service mean the market is characterized by high barriers to entry. Companies in this market continue to expand their cell/gene therapy service capabilities and geographic reach to meet rising customer demand.

Here's Free Sample Report Pdf: https://theresearchdeck.com/report/cell-and-gene-therapy-cro-service-market/#requestForSample

In summary, cell/gene therapy CROs provide the outsourced RD and manufacturing solutions that emerging biotech companies require to translate cutting-edge therapies from the lab into clinical testing and commercialization. The market opportunity is rapidly growing as more cell/gene treatments enter development pipelines.